The state of New Jersey currently has 18 active clinical trials seeking participants for Pancreatic Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT03334708
Recruiting
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey +1 locations
Conditions: Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
Register for Updates
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
NCT02674100
Recruiting
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users hav... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Atlantic Health, Millburn, New Jersey
Conditions: Pancreatic Cancer
Register for Updates
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
NCT04672005
Recruiting
The main objective of the clinical trial is to determine if modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel (mGnabP) administered as a combined, front-line therapy will result in longer time to treatment failure (TTF) compared to the current standard of care with mFFX alone in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey +6 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
NCT05360680
Recruiting
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Carol G. Simon Cancer Center - Morristown Medical Center, Morristown, New Jersey
Conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Register for Updates
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
NCT05415917
Recruiting
Primary Objectives: To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone. Secondary Objectives: To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS). To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates. To assess the quality of life in patients receivi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Pancreatic Cancer
Register for Updates
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: MD Anderson Cancer Center at Cooper Hospital, Camden, New Jersey +1 locations
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates